Where do Allogene Therapeutics's ratios come from?

Every ratio is computed from Allogene Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Returns
Return on equity	-53.4%+1.7pp	-55.1%+0.4pp	-55.5%-12.7pp	-42.8%-24.0pp
Return on assets	-39.6%+3.7pp	-43.2%+1.5pp	-44.7%-8.3pp	-36.4%-20.4pp
Return on invested capital	-56.5%+1.6pp	-58%-3.9pp	-54.2%-9.8pp	-44.4%-22.9pp
Efficiency
Asset turnover	0×—	0×0.0×	0×0.0×	0×-0.1×
Liquidity
Current ratio	7.9×-0.6×	8.5×-3.8×	12.4×+2.5×	9.8×0.0×
Quick ratio	7.9×-0.6×	8.5×-3.8×	12.4×+2.5×	9.8×0.0×
Cash ratio	1.9×-0.5×	2.4×-0.1×	2.5×+1.2×	1.3×-2.5×
Leverage
Debt-to-equity	0.3×+0.1×	0.2×0.0×	0.2×0.0×	0.2×+0.1×
Debt-to-assets	0.2×0.0×	0.2×0.0×	0.1×0.0×	0.1×+0.1×
Interest coverage	-194.7×+1,315×	-1,509.4×—	——	——
Per Share
Book value per share	$1.33-38.8%	$2.17-33.6%	$3.26-29.9%	$4.66-31.6%
Valuation
Market capitalization	$711.02M+164%	$446.6M-17.3%	$540.17M-40.4%	$907.08M-57.3%
Enterprise value	$751.47M+146%	$451.85M-16.6%	$541.84M-42.1%	$936.01M-53.6%
Price / book	2.5×+1.9×	1.1×0.0×	1.1×-0.3×	1.4×-0.9×
Free cash flow yield	-15.4%+58.2pp	-45%-0.7pp	-44.3%-19.4pp	-24.9%-15.2pp
Earnings yield	-24.4%+69.3pp	-57.7%+2.9pp	-60.6%-23.1pp	-37.5%-29.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Allogene Therapeutics's ratios come from?: Every ratio is computed from Allogene Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.